Literature DB >> 17923616

Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.

A Mellgren1, R W Price, L Hagberg, L Rosengren, B J Brew, M Gisslén.   

Abstract

OBJECTIVE: Increased levels of the light-chain neurofilament protein (NFL) in CSF provide a marker of CNS injury in several neurodegenerative disorders and have been reported in the AIDS dementia complex (ADC). We examined the effects of highly active antiretroviral treatment (HAART) on CSF NFL in HIV-1-infected subjects with and without ADC who underwent repeated lumbar punctures (LPs).
METHOD: NFL was measured by ELISA (normal reference value < 250 ng/L) in archived CSF samples from 53 patients who had undergone LPs before and after initiation of HAART.
RESULTS: Twenty-one of the subjects had increased CSF NFL at baseline, with a median level of 780 ng/L and an intraquartile range (IQR) of 480 to 7300. After 3 months of treatment, NFL concentrations had fallen to normal in 48% (10/21), and the median decreased to 340 ng/L (IQR < 250 to 4070) (p < 0.001), whereas at 1 year, only 4 of 16 of the 21 subjects observed for this length still had elevated NFL levels. Thirty-two subjects had normal NFL at baseline, and all but one remained normal at follow-up. These effects on CSF NFL were seen in association with clinical improvement in ADC patients, decreases in plasma and CSF HIV-1 RNA and CSF neopterin, and increases in blood CD4 T cell counts.
CONCLUSION: HAART seems to halt the neurodegenerative process(es) caused by HIV-1, as shown by the significant decrease in CSF NFL after treatment initiation. CSF NFL may serve as a useful marker in monitoring CNS injury in HIV-1 infection and in evaluating CNS efficacy of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923616     DOI: 10.1212/01.wnl.0000277635.05973.55

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

Review 1.  YKL-40: a candidate biomarker for simian immunodeficiency virus and human immunodeficiency virus encephalitis?

Authors:  Dennis L Kolson
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

2.  Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.

Authors:  Viktor Dahl; Julia Peterson; Dietmar Fuchs; Magnus Gisslen; Sarah Palmer; Richard W Price
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

3.  Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.

Authors:  Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu
Journal:  J Neurovirol       Date:  2018-11-26       Impact factor: 2.643

4.  The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease.

Authors:  Leah H Rubin; Erin E Sundermann; David J Moore
Journal:  J Neurovirol       Date:  2019-01-22       Impact factor: 2.643

Review 5.  Paving the path to HIV neurotherapy: Predicting SIV CNS disease.

Authors:  Sarah E Beck; Suzanne E Queen; Kenneth W Witwer; Kelly A Metcalf Pate; Lisa M Mangus; Lucio Gama; Robert J Adams; Janice E Clements; M Christine Zink; Joseph L Mankowski
Journal:  Eur J Pharmacol       Date:  2015-03-24       Impact factor: 4.432

6.  Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection.

Authors:  Michael J Peluso; Victor Valcour; Jintanat Ananworanich; Pasiri Sithinamsuwan; Thep Chalermchai; James L K Fletcher; Sukalya Lerdlum; Nitiya Chomchey; Bonnie Slike; Napapon Sailasuta; Magnus Gisslén; Henrik Zetterberg; Serena Spudich
Journal:  J Infect Dis       Date:  2015-05-20       Impact factor: 5.226

7.  Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage.

Authors:  E R Zanier; D Refai; G J Zipfel; T Zoerle; L Longhi; T J Esparza; M L Spinner; R J Bateman; D L Brody; N Stocchetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-22       Impact factor: 10.154

8.  Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.

Authors:  Elham Rahimy; Fang-Yong Li; Lars Hagberg; Dietmar Fuchs; Kevin Robertson; Dieter J Meyerhoff; Henrik Zetterberg; Richard W Price; Magnus Gisslén; Serena Spudich
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 5.226

9.  Diagnostic and prognostic biomarkers for HAND.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2019-01-03       Impact factor: 2.643

Review 10.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.